Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer-Reference-Cited by-同舟云学术

Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer

Published:2014-12-27 Issue:2 Volume:75 Page:401-410
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Borin Marie T.,Chen Meng,Mocci Simonetta,Rubets Igor,Chittenden Jason,Aldairy Wassim,Stroh Mark

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-014-2652-0.pdf

Reference21 articles.

1. Zagouri F, Bago-Horvath Z, Rössler F et al (2013) High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 108:1100–1105

2. Ho-Yen CM, Green AR, Rakha EA, Brentnall AR, Ellis IO, Kermorgant S, Jones JL (2014) C-Met in invasive breast cancer: is there a relationship with the basal-like subtype? Cancer 120:163–171

3. Kim JY, Choi JS, Seo J et al (2014) MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. Int J Cancer 134:2424–2436

4. Salgia R, Patel P, Bothos J et al (2014) Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res 20:1666–1675

5. Spigel DR, Ervin TJ, Ramlau RA et al (2013) Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31:4105–4114

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dostarlimab, an anti‐programmed death‐1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration‐QT analysis;British Journal of Clinical Pharmacology;2023-03-20

2. Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress;Frontiers in Oncology;2021-09-09

3. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2017-01

4. Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature;World Journal of Gastroenterology;2016

5. The use of combinations of monoclonal antibodies in clinical oncology;Cancer Treatment Reviews;2015-12